|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MEMBRANE TRANSPORTERS, ION CHANNELS, AND PUMPS
1Departments of Medicine and Physiology/Biophysics, University of California, Irvine, California; and 2Department of Medical Research, Veterans Affairs Medical Center, Long Beach, California
Submitted 10 January 2008 ; accepted in final form 4 March 2008
| ABSTRACT |
|---|
|
|
|---|
colonic transport; transport mechanism; transport regulation
Vitamin B6 is synthesized by plant cells and most unicellular microorganisms, but humans and other mammals cannot synthesize the vitamin and thus must obtain it from exogenous sources via intestinal absorption. Two sources of vitamin B6 are available to the intestine: a dietary source and a bacterial source; the latter source is in reference to the vitamin B6 that is produced by the normal microflora of the large intestine. The mechanism of absorption of dietary vitamin B6 in the small intestine has been studied using a variety of small intestinal preparations (8, 14, 15, 20, 23), with recent findings showing the existence of an efficient and specific carrier-mediated mechanism (20, 23). Nothing, however, is known about the mechanism of uptake of the bacterially produced vitamin B6 in the large intestine, where a significant amount of the vitamin is produced and exists in the free form in the surrounding medium (i.e., rather than being trapped within the bacterial cells) (16) and thus is available for absorption. Evidence suggesting that this source of vitamin B6 is indeed bioavailable to the host comes from studies showing that the amount of the vitamin that is excreted is significantly higher than the total amount consumed orally (11). Our aim in the present study was to investigate the mechanism involved in vitamin B6 (pyridoxine) uptake by mammalian colonocytes using the young adult mouse colonic epithelial (YAMC) cells and purified human colonic apical membrane vesicles (AMV) as models. The results showed, for the first time, the existence of a specific carrier-mediated mechanism for pyridoxine in mammalian colonocytes, which appears to be under extracellular and intracellular regulation.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell culture and uptake assays. YAMC, conditionally immortalized murine colonic epithelial cells, were maintained at 33°C in Dulbecco's modified Eagle's medium (DMEM) without added pyridoxine (Life Technologies). Media were supplemented with 10% fetal bovine serum (FBS), glutamine (0.29 g/l), sodium bicarbonate (3.7 g/l), penicillin (100,000 U/l), and streptomycin (10 mg/l). Purified human colonic membrane vesicles were obtained from Dr. Pradeep Dudeja (University of Illinois at Chicago, Chicago, IL) and were isolated from organ donors as described by us previously (5). [3H]pyridoxine uptake in colonic membrane vesicle was measured at room temperature for 1 min by rapid filtration method (9) as previously described (5). Routine [3H]pyridoxine uptake assay was performed using confluent monolayer (3–4 days after confluence) of YAMC in a 12-well plate. Protein concentrations were estimated on parallel wells using a protein assay kit (Bio-Rad). To determine the degree of pyridoxine metabolism after uptake by YAMC cells, a thin-layer chromatography (TLC) procedure employing cellulose gel-precoated plates and a solvent system of isopropanol/0.5 M acetate buffer (pH 4.5)/water (65/15/20, vol/vol/vol) was used as described previously (22, 23).
Statistical analysis. Data of all uptake experiments are the results of at least three independent determinations and are expressed as means ± SE (in pmol·mg protein–1·unit time–1 or fmol·mg protein–1·unit time–1). Statistical analysis was performed using ANOVA or Students t-test, with a significant P value set at <0.05. Kinetic parameters of the saturable component of pyridoxine uptake were determined by subtracting the diffusion component [calculated from the slope of the line between uptake at high concentration (1 mM) and the point of origin] from total uptake; data were then applied to a computerized model of the Michaelis-Menten equation as described previously (26).
| RESULTS |
|---|
|
|
|---|
|
|
The effect of incubation temperature on [3H]pyridoxine uptake by YAMC cells was also examined. Uptake was found to be highly temperature dependent, with a higher uptake at 37°C compared with 22°C (760 ± 50 and 220 ± 10 fmol·mg protein–1·3 min–1, respectively).
The metabolic form of the transported radioactivity taken by confluent YAMC cells following 10-min incubation with [3H]pyridoxine (75 nM) was examined by means of TLC (see MATERIALS AND METHODS), with the majority (96%) of the transported substrate found to be in the form of intact pyridoxine.
Evidence for existence of a carrier-mediated process for pyridoxine uptake by colonocytes. The initial rate of pyridoxine uptake as a function of substrate concentration (0.1- 10 µM) was examined, with the results showing evidence for the existence of a saturable uptake process (Fig. 3). Kinetic parameters of the saturable components were determined as described in MATERIALS AND METHODS and were found to be 2.1 ± 0.5 µM and 53.4 ± 4.3 pmol·mg protein–1·3 min–1 for the apparent Km and Vmax, respectively. This finding suggests involvement of a carrier-mediated process for pyridoxine uptake by YAMC cells. To further confirm the existence of a carrier-mediated system for pyridoxine uptake and to develop an understanding of its specificity, we examined the effect of unlabeled pyridoxine and that of its related compounds pyridoxal, pyridoxal 5-phosphate, and pyridoxamine, as well as that of the unrelated isoniazid, penicillamine, theophylline, and homocystine (all at 50 µM) on the initial rate of [3H]pyridoxine (15 nM) uptake. The results showed that while unlabeled pyridoxine, pyridoxal, pyridoxal 5-phosphate, and pyridoxamine all cause significant (P < 0.01) inhibition in [3H]pyridoxine uptake, no such effect was seen with isoniazid, penicillamine, theophylline, and homocystine (Fig. 4).
|
|
We also aimed at establishing the existence of a carrier-mediated process for pyridoxine uptake in native human colonocytes. To this end, we used purified native human proximal colonic AMV isolated by an established procedure from the colonic mucosa of human organ donors (5) and examined the effect of unlabeled pyridoxine (1 mM) on the initial rate of [3H]pyridoxine (250 nM) uptake. Significant (P < 0.01) inhibition in [3H]pyridoxine uptake by unlabeled pyridoxine was observed (Fig. 5).
|
The membrane transport inhibitor amiloride has been shown to inhibit pyridoxine uptake in mammalian and other cellular systems (3, 4, 22–24). We therefore examined its effect and that of other membrane transport inhibitors (DIDS and probenecid) on the initial rate of [3H]pyridoxine (15 nM) uptake by YAMC cells. The results showed amiloride to cause a significant (P < 0.01) and concentration-dependent inhibition in pyridoxine uptake (737 ± 49, 297 ± 60, and 227 ± 56 fmol·mg protein–1·3 min–1 for control and in the presence of 0.1 and 1 mM amiloride, respectively). On the other hand, neither DIDS nor probenecid was found to affect the initial rate of pyridoxine uptake (737 ± 49, 720 ± 60, and 720 ± 50 fmol·mg protein–1·3 min–1 for control and in the presence of DIDS and probenecid, respectively).
Possible regulation of the colonic pyridoxine uptake. In these investigations, we examined whether the pyridoxine uptake process of the YAMC cells is regulated by extracellular and intracellular factors. The extracellular factor that was selected for testing was increased extracellular pyridoxine level; YAMC cells were maintained (for 48 h) in a growth medium in the absence and presence of oversupplemented level (100 µM) of unlabeled pyridoxine. The results showed [3H]pyridoxine (15 nM) uptake by cells maintained in the presence of high pyridoxine level to be significantly (P < 0.01) lower than that of cells maintained in its absence (310 ± 30 and 930 ± 50 fmol·mg protein–1·3 min–1, respectively). This effect was specific for pyridoxine because uptake of the unrelated folic acid (8.6 nM; pH 5.5) was similar under the two pyridoxine-level conditions (1,840 ± 30 and 1,880 ± 70 fmol·mg protein–1·3 min–1 for cell growth in the absence and presence of pyridoxine oversupplementation, respectively). To determine the level at which this adaptive regulation in the pyridoxine uptake process is taking place, we first maintained YAMC cells (for 24 h) in pyridoxine-oversupplemented (100 µM) medium, then moved them to a medium that lacks pyridoxine oversupplementation in the absence or presence of the transcription inhibitor actinomycin D (0.23 µM) or the translational inhibitor cyclohexamide (40 µM). Incubation was then continued for an additional 24 h, followed by examination of the initial rate of [3H]pyridoxine (15 nM) uptake. As before, the uptake of cells maintained in the absence of pyridoxine oversupplementation was significantly (P < 0.01) higher than the uptake of cells maintained in the presence of pyridoxine oversupplementation. This induction in pyridoxine uptake was significantly (P < 0.01 for both) inhibited in the presence of actinomycin D and cyclohexamide in the growth medium (Fig. 6).
|
| DISCUSSION |
|---|
|
|
|---|
The initial rate of pyridoxine uptake by YAMC cells was saturable as a function of increasing the substrate concentration in the incubation medium (apparent Km = 2.1 ± 0.5 µM), suggesting involvement of a carrier-mediated mechanism in the uptake process. This suggestion was confirmed by the finding of a significant cis-inhibition in the initial rate of [3H]pyridoxine uptake by unlabeled pyridoxine and the pyridoxine-related compounds pyridoxal, pyridoxal 5-phosphate, and pyridoxine. Furthermore, the ability of unlabeled pyridoxine to trans-stimulate [3H]pyridoxine efflux from preloaded YAMC cells lent further support for the involvement of a carrier-mediated mechanism. The inability of the unrelated penicillamine, theophylline, and homocystine to affect the initial rate of [3H]pyridoxine uptake by YAMC cells demonstrates specificity of the colonic pyridoxine uptake process. In addition, since penicillamine, theophylline, and isoniazid are known inhibitors of the cytoplasmic pyridoxine kinase (which converts unphosphorylated forms of vitamin B6 into phosphorylated forms) (10, 12) and since the initial rate of pyridoxine uptake occurs without metabolic alterations, it is reasonable to conclude that intracellular phosphorylation of the transported substrate is not involved in pyridoxine uptake by colonic epithelial cells under our experimental conditions. Not only colonocytes of mouse origin, but also human colonocytes appear to have a functional pyridoxine uptake mechanism. This conclusion is based on the observation of a significant inhibition in [3H]pyridoxine uptake by unlabeled pyridoxine in purified native human colonic AMV isolated from the colonic mucosa of organ donors.
Previous studies have shown the pyridoxine uptake process of a number of prokaryotic and eukaryotic systems to be sensitive to the presence of amiloride (3, 4, 22–24). Our findings in the present study show that the YAMC cells are not an exception to these findings because significant inhibition in pyridoxine uptake was observed in the presence of this diuretic agent in the incubation medium. Whether amiloride also interacts with the colonic pyridoxine uptake process in vivo is not clear and requires further investigation.
The colonic pyridoxine uptake process appears to be regulated by extracellular and intracellular factors. Extracellular pyridoxine level appears to exert a marked effect on pyridoxine uptake by YAMC cells. This conclusion is based on the observation that maintaining these cells in a growth medium in the absence of pyridoxine oversupplementation led to a significantly higher uptake in [3H]pyridoxine compared with uptake by cells maintained in the presence of pyridoxine oversupplementation. Similar upregulation was seen with certain other water-soluble vitamin transport in a variety of cellular systems [i.e., folate, thiamine, biotin, and riboflavin transport (1, 18, 19, 21)]. This increase in pyridoxine uptake in the absence of pyridoxine oversupplementation appears to be mediated via transcriptional/translational mechanism(s). The latter suggestion is based on the findings that the presence of actinomycin D (a transcription inhibitor) and cyclohexamide (a translation inhibitor) inhibited the induction in pyridoxine uptake caused by switching the maintenance condition of the cells from high to low pyridoxine levels. Further studies are required to delineate the exact molecular mechanism(s) involved in this adaptive response of the pyridoxine colonic uptake process by substrate availability. The colonic pyridoxine uptake process also appeared to be under intracellular regulation. This suggestion is based on the observations of inhibition in pyridoxine uptake by inhibitors of the intracellular Ca2+/CaM-mediated pathway. The cellular and molecular mechanisms that mediate the Ca2+/CaM-mediated regulation of pyridoxine uptake by colonic epithelial cells are not known, and further studies are required to address these issues. Other intracellular regulatory pathways, like the PKA-, PKC-, and NO-mediated pathways, however, appeared to exert no regulatory effect on pyridoxine uptake. These findings are similar to those observed for the pyridoxine uptake process in renal epithelial cells but are different from the findings seen with the enterocyte Caco-2 cells, where a PKA- but not a Ca2+/CaM-mediated pathway was found to play a role in the regulation of pyridoxine uptake (22, 23). These findings suggest that different cells use different intracellular mechanisms to regulate pyridoxine uptake.
In summary, our results show for the first time the functional existence of a specific carrier-mediated mechanism for pyridoxine uptake by mammalian colonocytes. In addition, the results show that this uptake process is regulated by extracellular and intracellular factors.
| GRANTS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
* Z. M. Said and V. S. Subramanian contributed equally to this work. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Bilski P, Li MY, Ehrenshaft M, Daub ME, Chignell CF. Vitamin B6 (pyridoxine) and its derivatives are efficient single oxygen quenchers and potential fungal antioxidants. Photochem Photobiol 71: 129–134, 2000.[CrossRef][Web of Science][Medline]
3. Bowman BB, McCormick DB. Pyridoxine uptake by rat renal proximal tubular cells. J Nutr 119: 745–749, 1989.
4. Bowman BB, McCormick DB, Smith ER. Vitamin B6 uptake by rat kidney cells and brush-border membrane vesicles. Ann NY Acad Sci 585: 106–109, 1990.[Web of Science][Medline]
5. Dudeja PK, Torania SA, Said HM. Evidence for the existence of a carrier-mediated folate uptake mechanism in human colonic luminal membranes. Am J Physiol Gastrointest Liver Physiol 272: G1408–G1415, 1997.
6. Ehrenshaft M, Bilski P, Li MY, Chignell CF, Daub ME. A highly conserved sequence is a noval gene involved in de novo vitamin B6 biosynthesis. Proc Natl Acad Sci USA 96: 9374–9378, 1999.
7. Gospe SM. Pyridoxine-dependent seizures: findings from recent studies pose new questions. Pediatr Neurol 26: 181–185, 2002.[CrossRef][Web of Science][Medline]
8. Hamm MW, Hehansho H, Henderson LM. Transport and metabolism of pyridoxamine and pyridoxamine phosphate in the small intestine. J Nutr 109: 1552–1559, 1979.
9. Hopfer U, Nelson K, Perrotto J, Isselbacher KJ. Glucose transport in isolated brush border membrane from rat small intestine. J Biol Chem 248: 25–32, 1973.
10. Laine-Cessac P, Caillleux A, Allain P. Mechanisms of the inhibition of human erythrocyte pyridoxal kinase by drugs. Biochem Pharmacol 54: 863–870, 1997.[CrossRef][Web of Science][Medline]
11. Linkswiler H, Baumann CA, Snell EE. Effect of aureomycin on the response of rats to various forms of vitamin B6. J Nutr 43: 565–573, 1951.
12. McCormick DB, Guirard BM, Snell EE. Comparative inhibition of pyridoxal kinase and glutamic acid decarboxylase by carbonyl reagents. Proc Soc Exp Biol Med 104: 554–557, 1960.[CrossRef]
13. Merrill AH, Henderson M. Diseases associated with defects in vitamin B6 metabolism or utilization. Annu Rev Nutr 7: 137–156, 1987.[CrossRef][Web of Science][Medline]
14. Middleton HM. Intestinal absorption of pyridoxal-5' phosphate disappearance from perfused segments of rat jejunum in vivo. J Nutr 109: 975–981, 1979.
15. Middleton HM. Uptake of pyridoxine by in vivo perfused segments of rat small intestine: a possible role for intracellular vitamin metabolism. J Nutr 115: 1079–1088, 1985.
16. Mitchell HK, Isbel ER. Intestinal bacterial synthesis as a source of B vitamin for the rat. Univ Texas Publ 4237: 125–134, 1942.
17. Mithani SK, Balch GC, Shiou SR, Whitehead RH, Datta PK, Beauchamp RD. Smad3 has a critical role in TGF-beta-mediated growth inhibition and apoptosis in colonic epithelial cells. J Surg Res 117: 296–305, 2004.[CrossRef][Web of Science][Medline]
18. Reidling JC, Said HM. Adaptive regulation of intestinal thiamin uptake: molecular mechanism using wild-type and transgenic mice carrying hTHTR-1 and -2 promoters. Am J Physiol Gastrointest Liver Physiol 288: G1127–G1134, 2005.
19. Reidling JC, Nabokina SM, Said HM. Molecular mechanism involved in the adaptive regulation of human intestinal biotin uptake: a study of the hSMVT systems. Am J Physiol Gastrointest Liver Physiol 292: G275–G281, 2007.
20. Said HM. Recent advances in carrier-mediated intestinal absorption of water-soluble vitamins. Annu Rev Physiol 66: 419–446, 2004.[CrossRef][Web of Science][Medline]
21. Said HM, Ortiz A, Moyer MP, Yanagawa N. Riboflavin uptake by human-derived colonic epithelial NCM460 cells. Am J Physiol Cell Physiol 278: C270–C276, 2000.
22. Said HM, Ortiz A, Vaziri ND. Mechanism and regulation of vitamin B6 uptake by renal tubular epithelia: studies with cultured OK cells. Am J Physiol Renal Physiol 282: F465–F471, 2002.
23. Said HM, Ortiz A, Ma TY. A carrier-mediated mechanism for pyridoxine uptake by human intestinal epithelial Caco-2 cells: regulation by a PKA-mediated pathway. Am J Physiol Cell Physiol 285: C1219–C1225, 2003.
24. Stolz J, Wohrmann HJP, Vogal C. Amiloride uptake and toxicity in fission yeast are caused by the pyridoxine transporter encoded by bsu1+ (car1+). Eukaryot Cell 4: 319–326, 2005.
25. Whitehead RH, Vaneeden PE, Noble Ataliotis P MD, Jat PS. Establishment of conditionally immortalized epithelial cell lines from both colon and small intestine of adult H-2Kb-tsA58 transgenic mice. Proc Natl Acad Sci USA 90: 587–591, 1993.
26. Wilkinson GN. Statistical estimation in enzyme kinetics. Biochem J 80: 324–332, 1961.[Web of Science][Medline]
This article has been cited by other articles:
![]() |
J. E. Lee, H. Li, E. Giovannucci, I-M. Lee, J. Selhub, M. Stampfer, and J. Ma Prospective Study of Plasma Vitamin B6 and Risk of Colorectal Cancer in Men Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1197 - 1202. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |